Contact us

S*BIO Initiate Global P3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of MF

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now
  • en
  • cn

    • English

    • English
    • Chinese

    © 2021- edbi. All rights reserved.